Amplia Therapeutics (ASX: ATX) Webcast Replay
Amplia Therapeutics (ASX: ATX) is an Australian pharmaceutical company developing new drugs for cancer and fibrosis.
As a part of our ‘Meet the CEOs’ series, Chief Executive Officer Dr John Lambert provides valuable insights to the company, key markets and industry, and company’s future prospects.
Recorded on 21 October 2020 at 12pm (AEDT).
Join the next The Insider – Meet the CEOs webcast
FEATURE SPEAKERS
DR JOHN LAMBERT
Chief Executive Officer - Amplia Therapeutics (ASX: ATX)
Amplia Therapeutics (ASX: ATX) is an Australian pharmaceutical company developing new drugs for cancer and fibrosis. The drugs target a protein called Focal Adhesion Kinase (FAK) which is an increasingly important target in cancer biology. Amplia has a particular product development focus in pancreatic and ovarian cancer as well as life-threatening chronic diseases, such as idiopathic pulmonary fibrosis (IPF). The company recently announced the initiation of clinical trials of its lead candidate, AMP945.
